{"id":486508,"date":"2024-01-15T13:02:18","date_gmt":"2024-01-15T18:02:18","guid":{"rendered":"https:\/\/platohealth.ai\/scale-your-top-digital-stars-in-2024-not-just-generate-new-ones\/"},"modified":"2024-01-15T14:35:33","modified_gmt":"2024-01-15T19:35:33","slug":"scale-your-top-digital-stars-in-2024-not-just-generate-new-ones","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/scale-your-top-digital-stars-in-2024-not-just-generate-new-ones\/","title":{"rendered":"Scale Your Top Digital Stars in 2024\u2014Not Just Generate New Ones","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"
Jessica Jarvis and Daniel Blessing<\/em><\/p>\n<\/div>\n<\/div>\n One prediction for 2024 that may go unnoticed but should not is that the top players in pharma will begin to scale up the results they\u2019re getting with data, digital, and artificial intelligence (AI). The idea of scale\u2014taking the innovations that only happen in some parts of an organization and helping them happen elsewhere\u2014is not a novel one, but it\u2019s still an essential concept when it comes to generating value for an organization.<\/p>\n When we consider the idea of scale from the viewpoint of operating income, for example, we estimate that growing seven tested digital programs could generate $1.4 billion to $2.2 billion in five years for an average top 10 pharma company. This number could go higher, especially as generative AI is combined with existing approaches. But a sensible way to think about value is to understand how these programs already prove their worth and then mix generative AI with them to see how you can take things further.<\/p>\n In our work, seven programs stand out as crucial to boosting digital value. Each one strengthens the pharma value chain, impacting the core areas of clinical development, supply chain, and manufacturing and commercial engagement.If you haven\u2019t developed these, you are missing out on quick and significant ways to show how digital, technology, or AI drive measurable outcomes.<\/p>\n Figure:<\/strong> Essential digital programs that create meaningful value<\/p>\n<\/div>\n<\/div>\n The goals for the programs to scale in clinical development are to reduce study completion times, improve and diversify patient recruitment and retention, and lower costs to bring products to market.<\/p>\n A good test of your company\u2019s ability to create value here is to ask how well your teams can:<\/p>\n Today\u2019s best opportunities for scaling value exist in manufacturing and they are steps along the journey to optimize operations to support frequent nano and micro product launches<\/a>\u2014and eventually adopt autonomous manufacturing. All this work supports one goal: getting the right medicines to the right patients.<\/p>\n Good performance from your teams here means they regularly:<\/p>\n For commercial engagement,<\/strong> field teams know the importance of remaining relevant through more personalized, engaging experiences. Today\u2019s test for scaling value here depends on how well commercial teams can:<\/p>\n These programs need everyone to work together to grow, but with a clear strategy, they can show their worth in real dollars fairly quickly. And beyond the financial upsides, they offer significant opportunities for talent growth and help you build maturity for all future digital programs.<\/p>\n About the Authors<\/strong><\/p>\n Jessica Jarvis and Daniel Blessing are principals with ZS<\/a>, where they help organizations create meaningful value with data, digital and AI programs.<\/em><\/p>\n Jessica Jarvis and Daniel Blessing One prediction for 2024 that may go unnoticed but should not is that the top players in pharma will begin to scale up the results they\u2019re getting with data, digital, and artificial intelligence (AI). The idea of scale\u2014taking the innovations that only happen in some parts of an organization and […]<\/p>\n","protected":false,"gt_translate_keys":[{"key":"rendered","format":"html"}]},"author":2,"featured_media":486512,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[49],"tags":[],"acf":[],"gt_translate_keys":[{"key":"link","format":"url"}],"_links":{"self":[{"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/posts\/486508"}],"collection":[{"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/comments?post=486508"}],"version-history":[{"count":1,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/posts\/486508\/revisions"}],"predecessor-version":[{"id":486511,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/posts\/486508\/revisions\/486511"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/media\/486512"}],"wp:attachment":[{"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/media?parent=486508"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/categories?post=486508"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/tags?post=486508"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}<\/div>\n<\/div>\n<\/div>\n
The programs to scale<\/strong><\/h2>\n
<\/div>\n<\/div>\n<\/div>\n
Clinical development programs<\/strong><\/h2>\n
\n
Supply chain and manufacturing programs<\/strong><\/h2>\n
\n
Commercial programs<\/strong><\/h2>\n
\n
\n